The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent rep...

Descripción completa

Detalles Bibliográficos
Autor principal: Diamandis, Eleftherios P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425158/
https://www.ncbi.nlm.nih.gov/pubmed/22876833
http://dx.doi.org/10.1186/1741-7015-10-87
_version_ 1782241338555629568
author Diamandis, Eleftherios P
author_facet Diamandis, Eleftherios P
author_sort Diamandis, Eleftherios P
collection PubMed
description There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent reports (rare); true discoveries of biomarkers, that then fail to meet the demands of the clinic; and false discoveries, which represent artifactual biomarkers. I further provide examples of combinations of some known cancer biomarkers that can perform well in niche clinical applications, despite individually being not useful.
format Online
Article
Text
id pubmed-3425158
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34251582012-08-23 The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? Diamandis, Eleftherios P BMC Med Commentary There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent reports (rare); true discoveries of biomarkers, that then fail to meet the demands of the clinic; and false discoveries, which represent artifactual biomarkers. I further provide examples of combinations of some known cancer biomarkers that can perform well in niche clinical applications, despite individually being not useful. BioMed Central 2012-08-09 /pmc/articles/PMC3425158/ /pubmed/22876833 http://dx.doi.org/10.1186/1741-7015-10-87 Text en Copyright ©2012 Diamandis; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Diamandis, Eleftherios P
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title_full The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title_fullStr The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title_full_unstemmed The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title_short The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
title_sort failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425158/
https://www.ncbi.nlm.nih.gov/pubmed/22876833
http://dx.doi.org/10.1186/1741-7015-10-87
work_keys_str_mv AT diamandiseleftheriosp thefailureofproteincancerbiomarkerstoreachtheclinicwhyandwhatcanbedonetoaddresstheproblem
AT diamandiseleftheriosp failureofproteincancerbiomarkerstoreachtheclinicwhyandwhatcanbedonetoaddresstheproblem

Ejemplares similares